Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial

• Published in: Scientific reports Vol. 9; no. 1; p. 3755
• Main Authors: Sakamoto, Emi, Ishida, Waka, Sumi, Tamaki, Kishimoto, Tatsuma, Tada, Kentaro, Fukuda, Ken, Yoneda, Tsuyoshi, Kuroiwa, Hajime, Terao, Etsuko, Fujisawa, Yasuko, Nakakura, Shunsuke, Jian, Koji, Okumichi, Hideaki, Kiuchi, Yoshiaki, Fukushima, Atsuki
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 06.03.2019; Nature Publishing Group
• Subjects: 692/308/2779/109; 692/308/2779/109/1943; Blindness; Blood vessels; Clinical trials; Enzyme inhibitors; Eye; Glaucoma; Humanities and Social Sciences; Hyperemia; Hypertension; Kinases; multidisciplinary; Patients; Protein kinase inhibitors; Rho-associated kinase; Science; Science (multidisciplinary); Vision

Glaucoma leads to irreversible blindness. Numerous anti-glaucoma eye drops have been developed. Unfortunately, many patients with glaucoma still suffer from progressive visual disorders. Recently, ripasudil hydrochloride hydrate, a selective Rho-associated protein kinase inhibitor, was launched for...